Abstract
Background in 2010, the European Working Group on Sarcopenia in Older People (EWGSOP) published a sarcopenia definition that aimed to foster advances in identifying and caring for people with sarcopenia. In early 2018, the Working Group met again (EWGSOP2) to update the original definition in order to reflect scientific and clinical evidence that has built over the last decade. This paper presents our updated findings. Objectives to increase consistency of research design, clinical diagnoses and ultimately, care for people with sarcopenia. Recommendations sarcopenia is a muscle disease (muscle failure) rooted in adverse muscle changes that accrue across a lifetime; sarcopenia is common among adults of older age but can also occur earlier in life. In this updated consensus paper on sarcopenia, EWGSOP2: (1) focuses on low muscle strength as a key characteristic of sarcopenia, uses detection of low muscle quantity and quality to confirm the sarcopenia diagnosis, and identifies poor physical performance as indicative of severe sarcopenia; (2) updates the clinical algorithm that can be used for sarcopenia case-finding, diagnosis and confirmation, and severity determination and (3) provides clear cut-off points for measurements of variables that identify and characterise sarcopenia. Conclusions EWGSOP2's updated recommendations aim to increase awareness of sarcopenia and its risk. With these new recommendations, EWGSOP2 calls for healthcare professionals who treat patients at risk for sarcopenia to take actions that will promote early detection and treatment. We also encourage more research in the field of sarcopenia in order to prevent or delay adverse health outcomes that incur a heavy burden for patients and healthcare systems.
| Original language | English |
|---|---|
| Pages (from-to) | 16-31 |
| Number of pages | 16 |
| Journal | Age and Ageing |
| Volume | 48 |
| Issue number | 1 |
| Early online date | 24 Sept 2018 |
| DOIs | |
| Publication status | Published - Jan 2019 |
Funding
O Bruyére has received grants or consulting fees from Biophytis, IBSA, Servier, SMB, TRB Chemedica and UCB; he is also a shareholder for SarQoL sprl, a spin-off of the University of Liege. T. Cederholm has received unconditional research grants from Nestlé, Nutricia and Fresenius Kabi, and is giving lectures arranged by Nestlé, Nutricia, Fresenius Kabi and Abbott. A. Cherubini is giving presentations for and is consulting with Nestle. C Cooper has received lecture fees and honoraria from Amgen, Danone, Eli Lilly, GSK, Medtronic, Merck, Nestlé, Novartis, Pfizer, Roche, Servier, Shire, Takeda and UCB. A. Cruz-Jentoft has received speakers fees from Abbott Nutrition, Fresenius, Nestlé, Nutricia, Sanofi-Aventis; is a member of advisory boards for Abbott Nutrition, Boehringer Ingelheim Pharma, Nestlé, Pfizer and Regeneron; and has worked on research projects with Novartis, Nutricia, and Regeneron. J.-P. Michel is a speaker for Abbott Nutrition, and serves as a vaccine consultant to Pfizer and Merck. Y. Rolland is a consultant for Lactalis, Nestlé, Baxter, Novartis, and Biophytis. S Schneider reports honoraria from B. Braun, Fresenius Kabi, Grand-Fontaine, and Nestlé; he has also received honoraria and a grant from Nutricia. C.C. Sieber has received fees for presentations for and consulting with Abbott, Braun, Danone, Fresenius, Nestle, Nutricia, AMGEN, Berlin-Chemie, MSD, Novartis, Roche, Sevier and Vifor. M. Vandewoude is a lecturer for Nutricia. The following authors declare ‘none’ for potential conflicts of interest: J.P. Baeyens, G. Bahat, J. Bauer, I. Bautmans, Y. Boirie, M. Cesari, J.A. Kanis, F. Landi, M. Maggio, F.C. Martin, K. Pitkälä, J.-Y. Reginster, R. Rizzoli, D. Sánchez-Rodriguez, A.A. Sayer, J. Schols, E. Topinkova, M. Visser and M. Zamboni. The EuGMS received a grant from Abbott to fund the European Working Group on Sarcopenia in Older People 2 (EWGSOP2). This grant was used for operational activities of the EuGMS and for funding the two meetings of the Working Group. Abbott had no role in the choice of members of the group, but had the right to have observers at the meetings. Members of the Working Group received no salary or other incomes from the EuGMS, Abbott or any other organisation for any of the tasks involved in the preparation of this manuscript or for attending the meetings of the group. Abbott played no role in the preparation or approval of this manuscript.
| Funders | Funder number |
|---|---|
| Fresenius Kabi and Abbott | |
| Medical Research Council | MC_U147585819, MC_UP_A620_1014, MC_UU_12011/2, G0400491, MC_UP_A620_1015, MC_UU_12011/1, G0601019 |
| European Geriatric Medicine Society |
Keywords
- EWGSOP2
- muscle assessment
- muscle strength
- older people
- physical performance
- sarcopenia
